The prevailing view is that lack of EGFR mutation detection in the cfDNA of patients with advanced EGFR-mutated NSCLC might reflect low amounts of circulating tumor DNA, which can depend on various factors, including tumor burden, location of primary tumor and its metastasis, as well as an intrinsic nonshedder feature of the tumor. The gene discussed is EGFR; the disease is neoplasm.